Literature DB >> 23467193

Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders.

Nikolaus R McFarland1, Thomas Burdett, Cody A Desjardins, Matthew P Frosch, Michael A Schwarzschild.   

Abstract

BACKGROUND: Increasing evidence suggests that urate may play an important role in neurodegenerative disease. In Parkinson's disease (PD) higher, but still normal, levels of blood and cerebrospinal fluid urate have been associated with a lower rate of disease progression.
OBJECTIVE: We explored the hypothesis that lower levels of urate and its purine precursors in brain may be associated with PD and related neurodegenerative disorders, including Alzheimer's disease (AD) and Lewy body dementia (DLB).
METHODS: Human postmortem brain tissues were obtained from PD, AD, and DLB patients and non-neurodegenerative disease controls. We measured urate and other purine pathway analytes in the frontal and temporal cortex, striatum, and cerebellum, using high-performance liquid chromatography with electrochemical and ultraviolet detection.
RESULTS: Age was well-matched among groups. Mean postmortem interval for samples was 16.3 ± 9.9 h. Urate levels in cortical and striatal tissue trended lower in PD and AD compared to controls in males only. These findings correlated with increased urate in male versus female control tissues. By contrast, in DLB urate levels were significantly elevated relative to PD and AD. Measurement of urate precursors suggested a decrease in xanthine in PD compared to AD in females only, and relative increases in inosine and adenosine in DLB and AD samples among males. Xanthine and hypoxanthine were more concentrated in striatal tissue than in other brain regions.
CONCLUSIONS: Though limited in sample size, these findings lend support to the inverse association between urate levels and PD, as well as possibly AD. The finding of increased urate in DLB brain tissue is novel and warrants further study.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23467193      PMCID: PMC3809155          DOI: 10.1159/000346370

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  40 in total

1.  Clinical Lewy body dementia and the impact of vascular components.

Authors:  E Londos; U Passant; A Brun; L Gustafson
Journal:  Int J Geriatr Psychiatry       Date:  2000-01       Impact factor: 3.485

2.  Measurement of allantoin and uric acid in human body fluids. A potential index of free-radical reactions in vivo?

Authors:  M Grootveld; B Halliwell
Journal:  Biochem J       Date:  1987-05-01       Impact factor: 3.857

3.  Similar functions of uric acid and ascorbate in man?

Authors:  P Proctor
Journal:  Nature       Date:  1970-11-28       Impact factor: 49.962

4.  C9ORF72, the new gene on the block, causes C9FTD/ALS: new insights provided by neuropathology.

Authors:  Eileen H Bigio
Journal:  Acta Neuropathol       Date:  2011-12       Impact factor: 17.088

5.  Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation.

Authors:  W H Church; V L Ward
Journal:  Brain Res Bull       Date:  1994       Impact factor: 4.077

Review 6.  Oxidative stress in Parkinson's disease.

Authors:  Peter Jenner
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

Review 7.  Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma.

Authors:  Kyung-Jin Yeum; Robert M Russell; Norman I Krinsky; Giancarlo Aldini
Journal:  Arch Biochem Biophys       Date:  2004-10-01       Impact factor: 4.013

8.  Parkinson's Disease Society Brain Bank, London: overview and research.

Authors:  S E Daniel; A J Lees
Journal:  J Neural Transm Suppl       Date:  1993

9.  Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease.

Authors:  P Rinaldi; M C Polidori; A Metastasio; E Mariani; P Mattioli; A Cherubini; M Catani; R Cecchetti; U Senin; P Mecocci
Journal:  Neurobiol Aging       Date:  2003-11       Impact factor: 4.673

10.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis.

Authors:  B N Ames; R Cathcart; E Schwiers; P Hochstein
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

View more
  19 in total

Review 1.  Targeting urate to reduce oxidative stress in Parkinson disease.

Authors:  Grace F Crotty; Alberto Ascherio; Michael A Schwarzschild
Journal:  Exp Neurol       Date:  2017-06-13       Impact factor: 5.330

Review 2.  The relevance of gender in Parkinson's disease: a review.

Authors:  Marina Picillo; Alessandra Nicoletti; Vincenza Fetoni; Barbara Garavaglia; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neurol       Date:  2017-01-04       Impact factor: 4.849

Review 3.  Hyperuricemia, Gout, and the Brain-an Update.

Authors:  Augustin Latourte; Julien Dumurgier; Claire Paquet; Pascal Richette
Journal:  Curr Rheumatol Rep       Date:  2021-12-30       Impact factor: 4.592

4.  Prospective study of plasma urate and risk of Parkinson disease in men and women.

Authors:  Xiang Gao; Éilis J O'Reilly; Michael A Schwarzschild; Alberto Ascherio
Journal:  Neurology       Date:  2016-01-13       Impact factor: 9.910

Review 5.  A Dormant Microbial Component in the Development of Preeclampsia.

Authors:  Douglas B Kell; Louise C Kenny
Journal:  Front Med (Lausanne)       Date:  2016-11-29

6.  Glut9-mediated Urate Uptake Is Responsible for Its Protective Effects on Dopaminergic Neurons in Parkinson's Disease Models.

Authors:  Mingxia Bi; Qian Jiao; Xixun Du; Hong Jiang
Journal:  Front Mol Neurosci       Date:  2018-01-26       Impact factor: 5.639

Review 7.  The significance of uric acid in the diagnosis and treatment of Parkinson disease: An updated systemic review.

Authors:  Zhange Yu; Shuai Zhang; Dongdong Wang; Meng Fan; Fuqiang Gao; Wei Sun; Zirong Li; Shiliang Li
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

Review 8.  Uric Acid and Cognitive Function in Older Individuals.

Authors:  Claudio Tana; Andrea Ticinesi; Beatrice Prati; Antonio Nouvenne; Tiziana Meschi
Journal:  Nutrients       Date:  2018-07-27       Impact factor: 5.717

9.  Urate inhibits microglia activation to protect neurons in an LPS-induced model of Parkinson's disease.

Authors:  Li-Hui Bao; Ya-Nan Zhang; Jian-Nan Zhang; Li Gu; Hui-Min Yang; Yi-Ying Huang; Ning Xia; Hong Zhang
Journal:  J Neuroinflammation       Date:  2018-05-02       Impact factor: 8.322

10.  Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine.

Authors:  Hirohisa Watanabe; Tatsuya Hattori; Akito Kume; Kenichiro Misu; Takashi Ito; Yu Koike; Todd A Johnson; Shigeo Kamitsuji; Naoyuki Kamatani; Gen Sobue
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.